IgA Cutaneous Purpura Post–Renal Transplantation in a Patient With Long-Standing IgA Nephropathy

Sotoodian, Bahman; Robert, Janet; Mahmood, Muhammad Nateque; Yacyshyn, Elaine

doi:10.1177/1203475415582135

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many, rather old, clinical cases have been published. They describe episodes of one or the other disease within the same siblings, in particular in homozygous twins [ 1 ], simultaneously or successively [ 2 ], in a father and son [ 3 ], in the same patient at two periods of his life [ 4 , 5 , 6 , 7 ] and, more recently, recurrences in kidney allograft in one form or another [ 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

IgA Vasculitis and IgA Nephropathy: Same Disease?

Pillebout

2021

JCM

View full text Add to dashboard Cite

Many authors suggested that IgA Vasculitis (IgAV) and IgA Nephropathy (IgAN) would be two clinical manifestations of the same disease; in particular, that IgAV would be the systemic form of the IgAN. A limited number of studies have included sufficient children or adults with IgAN or IgAV (with or without nephropathy) and followed long enough to conclude on differences or similarities in terms of clinical, biological or histological presentation, physiopathology, genetics or prognosis. All therapeutic trials available on IgAN excluded patients with vasculitis. IgAV and IgAN could represent different extremities of a continuous spectrum of the same disease. Due to skin rash, patients with IgAV are diagnosed precociously. Conversely, because of the absence of any clinical signs, a renal biopsy is practiced for patients with an IgAN to confirm nephropathy at any time of the evolution of the disease, which could explain the frequent chronic lesions at diagnosis. Nevertheless, the question that remains unsolved is why do patients with IgAN not have skin lesions and some patients with IgAV not have nephropathy? Larger clinical studies are needed, including both diseases, with a common histological classification, and stratified on age and genetic background to assess renal prognosis and therapeutic strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

IgA Vasculitis and IgA Nephropathy: Same Disease?

Pillebout

2021

JCM

View full text Add to dashboard Cite

show abstract

“…HSPN is a systemic inflammatory response of small blood vessels, and its pathogenesis is not yet clear. There is direct evidence that food, environmental factors, infections, chemical exposure, drug allergies, insect bites, and other factors are all related to HSPN [ 18 ]. Some scholars believe that the above factors may cause the activated complement and immune complexes to be deposited in the glomerular mesangium and ultimately affect the normal physiological and metabolic mechanisms of blood coagulation to trigger the disease [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

The Efficacy of Tripterygium Glycosides Combined with LMWH in Treatment of HSPN in Children

Jin

Wang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. This study aimed to explore the clinical efficacy and relevant mechanism of Tripterygium glycosides combined with low molecular weight heparin calcium (LMWH) in the treatment of Henoch–Schönlein purpura nephritis (HSPN) in children. Methods. 64 cases of children patients with HSPN treated at Qilu Hospital (Qingdao) from January 2015 to May 2020 were selected and randomly divided into the control group and the observation group and 32 cases in each group. Conventional medical treatment was applied in the two groups, besides which the control group was given LMWH while the observation group was given Tripterygium glycosides based on the control group. The clinical efficacy and the indexes of clinical symptoms of the two groups were compared. Immune globulin level, fibrinogen content (FIB), prothrombin time (PT), platelet level (PLT), and activated partial thromboplastin time (APTT) level of the two groups were compared before and after the treatment. Results. The total effective rate in the observation group was significantly higher than that of the control group, and the recurrence rate in the observation group was lower than that in the control group. After treatment, urine red blood cell count and 24 h urine protein were obviously better than those of the control group. There was no statistically significant difference in PT between the two groups of children before and after treatment. The levels of PLT and FIB in the two groups of patients after treatment were significantly lower than before treatment, and the PLT levels in the observation group were lower than those in the control group. Conclusion. The combination of Tripterygium glycosides and LMWH had good clinical effects in the treatment of children with HSPN, and it could improve the clinical symptoms, the mechanism of which might be related to the increase of PT, a decrease of PLT, and the improvement of coagulation function.

show abstract